---
document_datetime: 2025-04-28 14:24:37
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/twynsta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: twynsta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1822365
conversion_datetime: 2025-12-28 18:46:10.10242
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Twynsta

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 28/04/2025                          |                                             | SmPC and PL                      | To update the Product Information by replacing the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000253062   | PRODUCTS - C.I.z Other variation - Accepted C.I.z (IB) - To update the Product Information by replacing the term \"antagonists\" with \"blockers\". Furthermore, the Marketing Authorisation Holder has taken the opportunity to update the list of local representatives and implement editorial changes in the BG and ES translations.   | term \"antagonists\" with \"blockers\".   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|